HELSINKI, FINLAND (MARCH 31, 2020) – MEGIN is pleased to announce the sale of our fourth-generation technology, the TRIUX™ neo, to the Chinese Academy of Science (CAS)’s Institute of Neuroscience (ION). This is our second MEG sale to China in the last six months, representing the expanding presence of MEGIN in China and reflects the increasing demand for Magnetoencephalography technology in that market.
This investment further supports China’s Brain Project, which was announced in March 2016 and has been established as a 15-year project. The neural basis of cognitive processes will be a central pillar of the project. Increasing resources are being devoted to the identification and evaluation of approaches to prevent, diagnose, and treat major brain diseases. Early diagnosis and intervention have been identified as the most effective approach to reducing disease burden to patients and overall society.
Megin strongly supports ION’s philosophy about the need for further research into the early diagnosis of neurological disorders and are proud that our technology will be instrumental in making advancements in this area and will contribute to the China Brain Project.
ION is devoted to research in all areas of basic neuroscience, including molecular, cellular and developmental neurobiology, systems and computational neuroscience, as well as cognitive and behavioural neuroscience. However, ION believes the structure and function of the brain pose the ultimate challenge to human understanding of nature and despite the spectacular progress in molecular and cellular biology over the last few decades, mysteries of the brain remain largely unsolved.
We’re pleased to work with CAS’s Institute of Neuroscience and are excited to see what pivotal work they complete with the TRIUX™ neo.
MEGIN, a Croton Healthcare company, is a neuroscience technology company based in Helsinki, Finland. The company is focused on developing innovative solutions for functional brain imaging for the presurgical evaluation of epilepsy, brain tumours or other lesions of the brain. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology and in 2018 launched their fourth-generation MEG system, TRIUX™ neo. The TRIUX neo provides a non-invasive, real-time view of patient specific neural activity with millimeter accuracy and millisecond resolution to provide the most precise information currently available on the market today.